南新制药(688189) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥21,308,086.94, a decrease of 40.45% compared to the same period last year[3]. - The total profit for the third quarter was -¥32,149,686.43, with a year-to-date total profit of -¥76,118,300.93, reflecting significant losses[3]. - The net profit attributable to shareholders for the third quarter was -¥28,631,491.51, down from -¥67,388,600.15 in the previous year[3]. - Total operating revenue for the first three quarters of 2025 was CNY 83,154,434.61, a decrease of 66.9% compared to CNY 251,110,585.69 in the same period of 2024[19]. - Net loss for the first three quarters of 2025 was CNY 75,777,289.57, compared to a net loss of CNY 65,925,432.36 in the same period of 2024, indicating a worsening of 14.1%[20]. - The basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.2501, compared to CNY -0.2089 in 2024, indicating a decline in earnings performance[21]. Research and Development - Research and development expenses totaled ¥9,746,614.10 for the third quarter, a decrease of 61.66% year-over-year, with R&D expenses accounting for 45.74% of operating revenue[3]. - Research and development expenses for the first three quarters of 2025 were CNY 27,300,905.81, slightly up from CNY 26,325,369.38 in 2024, representing an increase of 3.7%[20]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥75,223,063.51, an increase of 149.83% compared to the previous year[3]. - Cash received from sales of goods and services in the first three quarters of 2025 was CNY 186,545,063.10, down from CNY 257,971,161.66 in 2024, a decrease of 27.6%[23]. - Cash received from other operating activities was $18,955,390.12, up from $12,103,123.17, indicating improved operational cash generation[24]. - The ending cash and cash equivalents balance was $422,663,108.40, compared to $388,506,660.17 previously, showing a slight increase in liquidity[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,033,888,431.00, a decrease of 15.42% from the previous year-end[4]. - The total liabilities decreased from CNY 344,132,614.55 in 2024 to CNY 233,328,012.55 in 2025, a reduction of 32.2%[16]. - The total equity attributable to shareholders decreased from CNY 936,592,121.87 in 2024 to CNY 865,990,145.96 in 2025, a decline of 7.5%[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,114[8]. - Hunan Pharmaceutical Development Investment Group Co., Ltd. holds 28.57% of shares, totaling 78,400,000 shares[9]. - The company has repurchased a total of 265,516 shares, representing 0.10% of the total share capital, with a total expenditure of RMB 1,967,393.92[11]. Market Conditions - The company is currently facing increased market competition, which has significantly impacted sales and revenue[6]. Accounting and Reporting - The company identified an accounting error that reduced 2023 revenue by ¥24,539,700, representing 3.4% of total revenue for that year[4]. - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[26].